Lorcaserin

Serotonin-2c Receptor Agonist — ALIMENTARY TRACT AND METABOLISM

Key facts

Lorcaserin is a drug in the Serotonin-2c Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Cytochrome P450 2D6 Inhibitors and Serotonin 2c Receptor Agonists. DrugCentral lists 4 molecular targets, including HTR2C, HTR2A and HTR2B. Recorded indications include Obesity.

• Drug class: Serotonin-2c Receptor Agonist.
• Mechanism of action: Cytochrome P450 2D6 Inhibitors; Serotonin 2c Receptor Agonists.
• Molecular targets: HTR2C, HTR2A, HTR2B and SLC6A4 (4 listed in DrugCentral).
• Indications: Obesity.
• ATC code: A08AA11 (Centrally acting antiobesity products).
• Molecular formula: C11H14ClN; molecular weight 195.69 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Obesity

Contraindications (1)

• Pregnancy, function

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 2D6 Inhibitors; Serotonin 2c Receptor Agonists
• Established pharmacologic class: Serotonin-2c Receptor Agonist

Molecular targets (4)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 2C	HTR2C	agonist	Ki 7.89
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 7.04
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 6.83
Sodium-dependent serotonin transporter	SLC6A4	unknown	Ki 5.58

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2012-06-27	FDA	—	EISAI INC

ATC classification

ATC code	Therapeutic hierarchy
A08AA11	ALIMENTARY TRACT AND METABOLISM › ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS › ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS › Centrally acting antiobesity products

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Headache	145.7
Dizziness	86.1
Fatigue	76.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Lorcaserin is on its molecule page.

• Molecular formula: C₁₁H₁₄ClN
• Molecular weight: 195.69 g/mol
• CAS number: 616202-92-7
• InChIKey: XTTZERNUQAFMOF-QMMMGPOBSA-N
• PubChem CID: 11658860

C[C@H]1CNCCC2=CC=C(Cl)C=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lorcaserin used for?

DrugCentral lists the following indications for Lorcaserin: Obesity.

How does Lorcaserin work?

Lorcaserin is classified as Cytochrome P450 2D6 Inhibitors and Serotonin 2c Receptor Agonists; its molecular targets in DrugCentral include HTR2C (agonist), HTR2A, HTR2B and SLC6A4.

When was Lorcaserin first approved?

Lorcaserin was first approved by the FDA in 2012.

What drug class does Lorcaserin belong to?

Lorcaserin is in the Serotonin-2c Receptor Agonist class.

What is the chemical formula of Lorcaserin?

Lorcaserin has the molecular formula C11H14ClN and a molecular weight of 195.69 g/mol.

Sources

• DrugCentral drug card 4374 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2095211 — compound record and bioactivity
• PubChem CID 11658860 — chemical identifiers
• DrugBank DB04871 — drug record
• FDA UNII 637E494O0Z — substance identity
• DailyMed: FDA labels for Lorcaserin — current prescribing information (label search)
• UniProt P28335 (HTR2C) — target protein
• UniProt P28223 (HTR2A) — target protein
• UniProt P41595 (HTR2B) — target protein
• UniProt P31645 (SLC6A4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.